
## Robert L Gottlieb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1617805/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. New England Journal of Medicine, 2021, 384, 229-237.	27.0	1,130
2	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1048.	7.4	1,032
3	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine, 2022, 386, 305-315.	27.0	813
4	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 632.	7.4	803
5	Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology, 2021, 21, 382-393.	22.7	568
6	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. New England Journal of Medicine, 2021, 385, 1382-1392.	27.0	534
7	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	27.0	357
8	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clinical Infectious Diseases, 2021, 73, e4166-e4174.	5.8	135
9	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 622-635.	9.1	135
10	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Medicine, 2021, 47, 1258-1270.	8.2	88
11	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clinical Infectious Diseases, 2022, 75, e450-e458.	5.8	84
12	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	3.9	56
13	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clinical Infectious Diseases, 2022, 75, e440-e449.	5.8	46
14	A Selected Ribozyme Catalyzing Diverse Dipeptide Synthesis. Chemistry and Biology, 2002, 9, 619-628.	6.0	44
15	5â€~-Sulfhydryl-Modified RNA:  Initiator Synthesis, in Vitro Transcription, and Enzymatic Incorporation. Bioconjugate Chemistry, 2001, 12, 939-948.	3.6	34
16	Replication Initiator Protein NS1 of the Parvovirus Minute Virus of Mice Binds to Modular Divergent Sites Distributed throughout Duplex Viral DNA. Journal of Virology, 2007, 81, 13015-13027.	3.4	32
17	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open Forum Infectious Diseases, 2021, 8, ofab278.	0.9	31
18	Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): Multicenter experience of referral hospitals in a large health care system. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1071-1079.e3.	0.8	26

RobertÂL Gottlieb

#	Article	IF	CITATIONS
19	Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse. Journal of Cardiac Failure, 2017, 23, 765-767.	1.7	24
20	ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2–specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report. American Journal of Transplantation, 2022, 22, 1261-1265.	4.7	24
21	Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1290-1299.	5.6	19
22	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. Frontiers in Immunology, 2021, 12, 790469.	4.8	15
23	The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients. Current Transplantation Reports, 2018, 5, 145-152.	2.0	11
24	<i>De novo</i> tacrolimus extendedâ€release tablets (LCPT) versus twiceâ€daily tacrolimus in adult heart transplantation: Results of a singleâ€center nonâ€inferiority matched control trial. Clinical Transplantation, 2021, 35, e14487.	1.6	7
25	Ally in Fighting Covid-19: Magnitude of Albumin Decline and Lymphopenia (Ally) Predict Progression to Critical Disease. Journal of Investigative Medicine, 2021, 69, 710-718.	1.6	6
26	LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. Open Forum Infectious Diseases, 2021, 8, S806-S807.	0.9	6
27	Early psychological health outcomes among United States healthcare professionals, essential workers, and the general population during the COVID-19 pandemic: The influence of occupational status. Psychiatry Research Communications, 2021, 1, 100005.	1.0	5
28	Psychological differences in adults with and without a COVID-19 diagnosis. Journal of Mental Health, 2022, , 1-8.	1.9	4
29	Outpatient COVIDâ€19 surveillance testing in orthotopic heart transplant recipients. Clinical Transplantation, 2020, 34, e14105.	1.6	3
30	Acute myocardial infarction secondary to mucormycosis after lung transplantation. IDCases, 2021, 23, e01019.	0.9	3
31	Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 827-834.	2.4	3
32	The utility of boxing for cardiac prehabilitation. Baylor University Medical Center Proceedings, 2021, 34, 182-184.	0.5	2
33	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. Open Forum Infectious Diseases, 2022, 9, .	0.9	2
34	New molecular microscope archetypes: Will the real rejection please stand up?. Journal of Heart and Lung Transplantation, 2022, , .	0.6	2
35	Dynamic albumin values as clinical surrogate for COVID-19 therapeutics. Journal of Investigative Medicine, 2021, 69, 1260-1260.	1.6	1
36	72. Remdesivir vs Standard Care in Patients with Moderate covid-19. Open Forum Infectious Diseases, 2020. 7. S166-S167.	0.9	1

ROBERTÂL GOTTLIEB

#	Article	IF	CITATIONS
37	Stewardship of COVID-19 volunteers by nested trial design. Lancet Infectious Diseases, The, 2022, 22, 1400-1401.	9.1	1
38	Heartmate IIIâ,,¢ Implantation: A Novel Technique to Reduce the Incidence of Perioperative Bleeding and the Use of Intraoperative Blood Products. Journal of Heart and Lung Transplantation, 2020, 39, S445.	0.6	0
39	Impact of Ischemic Time on Functional Exercise Capacity after Orthotopic Heart Transplantation. Journal of Heart and Lung Transplantation, 2020, 39, S301.	0.6	0
40	The Olympiad of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccinology: Fundamentals to Complement Technical Frontiers. Clinical Infectious Diseases, 2021, 73, e3956-e3958.	5.8	0
41	73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir. Open Forum Infectious Diseases, 2020, 7, S167-S167.	0.9	0
42	38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality. Open Forum Infectious Diseases, 2021, 8, S27-S28.	0.9	0
43	Not all shock is created equal. American Journal of Emergency Medicine, 2021, 57, 188-188.	1.6	0